Blockchain Registration Transaction Record

HeartBeam to Showcase FDA-Cleared ECG Tech at JP Morgan Healthcare Conference

HeartBeam announces FDA-cleared cable-free 12-lead ECG tech for arrhythmia assessment, with CEO presenting at JP Morgan 2026 Healthcare Conference ahead of Q1 2026 U.S. launch.

This development matters because it represents a significant leap forward in accessible cardiac care. Heart disease remains a leading cause of death globally, and early detection of arrhythmias is crucial for preventing strokes, heart failure, and other serious complications. Traditional 12-lead ECGs require bulky, cable-connected machines typically found in hospitals or clinics, creating barriers to frequent monitoring. HeartBeam's cable-free, portable technology could enable more convenient, at-home monitoring, allowing for earlier detection of issues and potentially reducing hospital visits. For patients with known cardiac conditions or those at risk, this could mean more proactive management of their health. For the healthcare system, it offers a tool to potentially lower costs by catching problems earlier and reducing emergency interventions. The FDA clearance and planned commercial launch signal that this isn't just theoretical—it's nearing real-world application that could soon impact how cardiac care is delivered.